BioPharmX Corp fka BPMX

[Whos_Who]

BioPharmX Competitor Announces Positive Phase 3 Results

I believe this is positive news that helps the industry and our investment as well.

Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year

REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced positive safety data for its Phase 3 open-label safety extension study, evaluating FMX-101 in moderate-to-severe acne for a treatment period of up to 1 year.

The open-label safety extension enrolled a total of 657 patients, all of whom had completed 12 weeks of FMX-101 or vehicle treatment in the preceding double-blind phases of FX2014-04 or FX2014-05. Patients continued for up to an additional 40 weeks of open-label treatment with FMX-101.

291 patients completed a total of 52 weeks on FMX-101 therapy which is in excess of the subject sample size requirements specified in the regulatory guidance for this type of safety evaluation (ICH E1A, 1995). The key findings from the study are as follows:

Non-dermal adverse events were comparable in type and frequency with those reported during the double-blinded portion of FX2014-04 and FX2014-05. The most frequently reported treatment-emergent adverse event was nasopharyngitis (common cold). In the open-label extension, 3 patients discontinued the study for non-dermal adverse events – abdominal pain (2 patients), back pain (1 subject). No serious drug-related adverse events were reported.

Application site adverse events occurred in less than 2% of patients during the additional 40 weeks of open-label treatment with FMX-101. Four patients discontinued in the study for an application site adverse event – worsening of acne (2 patients), contact dermatitis (one subject), and localized facial edema (1 subject). In the assessment of facial dermal tolerability at Week 52, more than 95% of patients had “none” or “mild” signs and symptoms (erythema, dryness, hyperpigmentation, peeling, and itching), and no severe local tolerability scores were recorded.

Subject satisfaction with FMX-101 treatment remained high when re-assessed at Week 52 which was consistent with scores obtained at Week 12 (end of double-blind phase).
“We are extremely encouraged that our comprehensive safety evaluation of FMX-101 has validated earlier data demonstrating that FMX-101 appears to be well tolerated, with an acceptable safety profile and very positive patient survey results in the treatment of moderate-to-severe acne vulgaris,” said David Domzalski, CEO of Foamix.

Data from this study will be presented in a poster forum at the Winter Clinical Dermatology Conference to be held January 12th – 17th at the Hyatt Regency in Maui, Hawaii. In addition, Foamix will also present the following posters from the FMX-101 development program at the conference:

Pharmacokinetic Evaluation of Once-Daily Topical 4% Minocycline Foam in Adult and Pediatric Patients with Moderate-to-Severe Acne in Two Phase 1 Studies

The Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris: A Pooled Analysis of Two Phase 3 Studies

https://globenewswire.com/news-release/2018/01/04/1283300/0/en/Foamix-Announces-Positive-Results-from-Phase-3-Open-Label-Safety-Extension-Evaluating-FMX-101-Topical-Minocycline-Foam-for-Treatment-up-to-1-Year.html